Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

by Zacks Equity Research

Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

    Zacks Equity Research

    Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

    by Zacks Equity Research

    Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

      Zacks Equity Research

      Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?

      by Zacks Equity Research

      Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.

        Zacks Equity Research

        What Falling Estimates & Price Mean for ChromaDex (CDXC)

        by Zacks Equity Research

        ChromaDex (CDXC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

          Zacks Equity Research

          Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing

          by Zacks Equity Research

          Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.

            Zacks Equity Research

            Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

            by Zacks Equity Research

            Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.

              Zacks Equity Research

              Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?

              by Zacks Equity Research

              Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

                Zacks Equity Research

                AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

                by Zacks Equity Research

                AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

                  Zacks Equity Research

                  ResMed Releases Positive U.S. & U.K. Study Data on COPD

                  by Zacks Equity Research

                  ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.

                    Zacks Equity Research

                    Here's Why You Should Invest in Illumina (ILMN) Stock Now

                    by Zacks Equity Research

                    Illumina (ILMN) gains ground on product launches and international prospects.